In MDlinx written by Liz Meszaros,   Researchers have discovered the genetic fingerprint that may account for why up to 30% of men with potentially curable, localized prostate cancer go on to develop aggressive disease that spreads after radiotherapy or surgery. Their results are published online in Nature, and may help clinicians successfully personalize treatment with effective and targeted […]

Published in Urology Times   June 12, 2017 By Cheryl Guttman Krader, Wayne Kuznar     New findings from two large-scale, international studies support the use of upfront treatment with abiraterone acetate (ZYTIGA) in men with metastatic prostate cancer. The phase III international LATITUDE trial met its co-primary endpoints, demonstrating that adding abiraterone acetate plus prednisone (AA+P) to […]

John Murphy, MDLinx, 12/17/2015 Men with localized prostate cancer who were treated with radical prostatectomy surgery had better survival rates than those treated with radiotherapy, according to a meta-analysis that included nearly 120,000 patients. This result remained even after accounting for the type of radiation and the aggressiveness of cancer, researchers concluded in their study […]